External reports (aggregated public sources), Value Investors Club

Value Investors Club

External reports (aggregated public sources)

Equity Bottom-Up

<ul><li>Gotham City Research's short report on Grifols is seen as misguided, creating a buying opportunity for investors</li><li>Grifols is still viewed as a strong business with potential for significant growth in the next 12-18 months</li><li>With COVID headwinds normalizing and a new management team in place, Grifols is expected to see a 140% increase in stock price if it trades at historical average EBITDA multiple, making it a compelling long opportunity</li></ul><p><em>This content is sourced through publicly available sources and has been machine generated. Information displayed is for general informational purposes only. This article was originally published 3 months ago on Value Investors Club.</em></p>

Gotham City Research's short report on Grifols is seen as misguided, creating a buying opportunity for investorsGrifols is still viewed as a strong business with potential for significant growth in the next 12-18 monthsWith COVID headwinds normalizing and a new management team in place, Grifols is expected to see a 140% increase in stock price if it trades at historical average EBITDA multiple, making it a compelling long opportunityThis content is sourced through publicly available sources and has been machine generated. Information displayed is for general informational purposes only. This article was originally published 3 months ago on Value Investors Club.

Grifols S A (GRF/P SM) - Friday, Mar 22, 2024

Spain

Grifols S.A. develops, manufactures, and markets plasma derivatives, IV Therapy, enteral nutrition, diagnostic systems, and medical materials.

Laboratorios Farmaceuticos Rovi SA is a specialty pharmaceutical company. The Company researches, develops, manufactures, and markets small molecule and specialty biologic drugs. Rovi's services include contract manufacturing of aseptic filling and packaging of small-volume parenterals in prefilled syringes and vials and provides temperature-controlled storage facilities.

Laboratorios Farmaceuticos ROVI (ROVI SM)

Oryzon Genomics, SA is a clinical stage biopharmaceutical company that develops epigenetics-based therapeutics.

Almirall SA is an international pharmaceutical company. The Company produces allergy and respiratory, cardiovascular, central nervous system, digestive, infectious disease, oncology, osteomuscular, pediatric, and urology  drugs.

Faes Farma, S.A. develops, manufactures and markets pharmaceutical products throughout Spain and, through its subsidiary, Laboratorios Vitoria S.A., in Portugal. The Company's principal prescription products combat cardiovascular, respiratory, central nervous system, musculoskeletal and osteoporosis related ailments.

Biocon Ltd., is an integrated biotechnology enterprise with a presence in biopharmaceuticals, enzymes, custom research and clinical research. The Company's pharmaceutical products include statins, immunosuppressants and anti-diabetic drugs. Biocon also manufactures specialty enzymes and new enzyme applications besides providing clinical and custom research services.

Blueprint Medicines Corporation develops and distributes biomedical treatments. The Company researches and produces medicines and treatments for cancer targeting the molecular differences. Blueprint Medicines focuses selective drugs for genomically defined cancer patients.

Beijing Tiantan Biological Products Corporation Limited researches, develops, and commercializes biological products.  The Company provides treatment for hepatitis and offers a line of vaccine products including hepatitis vaccines and rubella vaccines.

Beijing Tiantan Biological Products (600161 CH)

Exact Sciences Corp., is focused on developing and commercializing a non-invasive molecular screening test for the early detection and prevention of colorectal cancer. The Company's test is a stool-based DNA test that identifies both pre-cancer and cancer by detecting genetic mutations in colorectal cancer cells.

Ionis Pharmaceuticals, Inc. operates as a biotechnology company. The Company researches in RNA-targeted drug discovery and development that focuses on drugs for patients who have unmet medical needs. Ionis Pharmaceuticals serves customers in the United States.

ImmunoGen, Inc. develops targeted anticancer therapeutics using its Targeted Antibody Payload (TAP) technology together with its expertise in monoclonal antibodies and tumor biology. A TAP compound uses a tumor-targeting monoclonal antibody to deliver one of  ImmunoGen's purpose-developed cancer-killing agents specifically to tumor cells.

Repligen Corporation is a bioprocessing company focused on the development, production, and commercialization of innovative products used in the process of manufacturing biologic drugs. The Company's customers include life sciences companies, global biopharmaceutical companies, and contract manufacturers worldwide.

Cytokinetics, Incorporated is a clinical-stage biopharmaceutical company.  The Company is focused on the discovery and development of novel small molecule therapeutics that modulate muscle function for the potential treatment of serious diseases and medical conditions.

IVERIC bio, Inc. operates as a biopharmaceutical company. The Company develops treatments for patients with orphan inherited retinal diseases with significant unmet medical needs. IVERIC bio serves customers in the United States.

PharmaEssentia Corporation develops and distributes therapeutic products for treatment in human disease. The Company develops drugs to treat hepatitis, chronic myeloid leukemia (CML), essential thrombocythemia (ET), myeloid fibrosis (MF), polycythemia vera (PV), hepatitis and cancer.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Grifols SA (GRF SM)

Grifols S A (GRF/P SM) - Friday, Mar 22, 2024

Gotham City Research's short report on Grifols is seen as misguided, creating a buying opportunity for investors. Grifols is still viewed as a...

Value Investors Club

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)